052670 — CHEIL BIO Co Income Statement
0.000.00%
HealthcareAdventurousMicro Cap
- KR₩61bn
- KR₩44bn
- KR₩14bn
Annual income statement for CHEIL BIO Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 18,999 | 16,912 | 15,349 | 12,111 | 13,908 |
| Cost of Revenue | |||||
| Gross Profit | 3,787 | 2,225 | 2,445 | 2,329 | 3,219 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19,487 | 18,639 | 16,919 | 14,129 | 14,985 |
| Operating Profit | -488 | -1,726 | -1,570 | -2,018 | -1,077 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1,230 | 138 | -1,756 | -1,464 | -411 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 994 | -712 | -1,708 | -1,446 | -417 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 994 | -712 | -1,708 | -1,446 | -417 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 994 | -712 | -1,708 | -1,446 | -417 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 35.3 | -25.2 | -60.1 | -53.5 | -15 |
| Dividends per Share |